LONDON, January 30, 2018 /PRNewswire/ --
REX-001 is a novel cell therapy for the treatment ofCritical Limb Ischemia (CLI), a disease which affects an estimated one million people in Europe
Rexgenero Ltd, a clinical-stage regenerative
Joe Dupere, Rexgenero's CEO, commented, "We are delighted to have been granted an ATMP certificate for manufacturing quality and non-clinical data for REX-001. This is a major milestone for us as we work to bring this novel cell therapy to patients diagnosed with CLI, a disease with high unmet medical needs. We believe that REX-001 has the potential to be one of the first effective cell therapy products available for patients with CLI, a disease strongly associated with a high risk of amputation and mortality."
Rexgenero received the certificate following a thorough scientific evaluation of the manufacturing quality data and non-clinical data by the EMA's Committee for Advanced Therapies (CAT).
Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs.
The Company's lead candidate REX-001 is a highly innovative autologous cell therapy that is being studied in a Phase III clinical programme in patients with Critical Limb Ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. REX-001 has been shown to be effective in Phase I/II and Phase II trials, alleviating CLI in the majority of patients, offering the potential to increase the quality of life of CLI patients by reducing pain, alleviating ulcers, increasing mobility, improving sleep and reducing the need for amputation. Rexgenero is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.
Rexgenero is a privately-owned company, which draws on an exceptional understanding of the fundamental science of cell therapies developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies.
The Company was founded in 2015 and is headquartered in London (UK) with R&D and manufacturing operations in Seville (Spain).
For more information, please visit www.rexgenero.com
Rexgenero Joe Dupere, CEO T: +44-(0)-203-709-1969 E: firstname.lastname@example.org
Citigate Dewe Rogerson Sylvie Berrebi, Shabnam Bashir T: +44-(0)-20-7638-9571 E: email@example.com
Subscribe to our Free Newsletters!
Hearing loss calculator is a quick online screening test to check for hearing loss. Result from ...
Home remedies such as baking soda, sugar, Epsom salt, black tea and castor oil exfoliate, soften ...
Immunosuppressant drugs suppress immunity. But why would you want to reduce immunity, which is ...View All